Alpha Emitter Market
Alpha Emitter Market Forecasts to 2030 - Global Analysis By Type (Lead, Astatine, Bismuth, Radium, Actinium and Other Types), Source, Application, End User and By Geography
According to Stratistics MRC, the Global Alpha Emitter Market is accounted for $678.4 million in 2023 and is expected to reach $1636.0 million by 2030 growing at a CAGR of 13.4% during the forecast period. An alpha emitter refers to a radioactive substance or isotope that undergoes alpha decay, emitting alpha particles during the process. Alpha particles consist of two protons and two neutrons, essentially equivalent to a helium-4 nucleus. This type of radioactive decay is characterized by the release of alpha particles from the atomic nucleus, resulting in the transformation of the original element into a new element with a lower atomic number. The use of alpha emitters has applications in various fields, including medicine, industry, and research.
According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and aging.
Market Dynamics:
Driver:
Rising awareness of alpha particle therapy
The market is experiencing a surge in awareness, particularly driven by the growing recognition of alpha particle therapy. As medical science advances, there is an increasing understanding of the therapeutic potential of alpha emitters in targeted cancer treatments. Alpha particle therapy delivers highly localized and potent radiation, enhancing its efficacy in treating certain types of cancers with minimal damage to surrounding healthy tissues. The rising awareness is likely to propel the demand for alpha emitters, driving further innovations and advancements in this field.
Restraint:
Short half-life of radiopharmaceuticals
The short half-life of radiopharmaceuticals in the market poses a challenge, limiting their effective application in medical and industrial settings. Rapid decay reduces the window of opportunity for administering treatments or conducting experiments, requiring efficient logistics and quick deployment. This constraint may impact the widespread adoption of alpha emitters, especially in scenarios where extended periods of radioactivity are crucial for desired outcomes, necessitating careful consideration of decay rates in planning and implementation.
Opportunity:
Advancements in nuclear medicine
Recent advancements in the market for nuclear medicine have focused on innovative targeted alpha-particle therapies. Alpha emitters exhibit high precision in cancer treatment by delivering localized radiation to tumour cells, minimizing damage to surrounding healthy tissues. These developments enhance the efficacy and safety of therapeutic interventions, marking significant progress in personalized medicine and improving outcomes for patients with certain types of cancer.
Threat:
Need for high capital investment
The market demands substantial capital investment due to the complex and specialized nature of alpha-emitting technologies. Establishing secure production facilities, ensuring compliance with stringent regulatory standards, and investing in advanced research and development for safe applications require significant financial resources. Additionally, the need for extensive safety measures and controlled environments adds to the overall high capital requirements, creating a barrier to entry for potential market participants.
Covid-19 Impact:
The COVID-19 pandemic has influenced the market by disrupting supply chains, delaying research and development projects, and impacting regulatory processes. The increased focus on healthcare during the pandemic has both positively and negatively affected the demand for alpha emitters used in medical applications. While the need for cancer treatments has grown, logistical challenges and prioritization of resources have presented obstacles. The overall market has experienced fluctuations due to the dynamic circumstances created by the global health crisis.
The bismuth segment is expected to be the largest during the forecast period
The bismuth segment is expected to be the largest during the forecast period. It is utilized in targeted alpha-particle radiotherapy for treating certain types of cancer. Its short half-life and ability to deliver high-energy alpha particles make it valuable for precise and effective cancer treatment. The increasing focus on innovative medical therapies has contributed to the growing demand for bismuth-213 and underscores its importance in advancing alpha emitter applications in the medical field.
The ovarian cancer segment is expected to have the highest CAGR during the forecast period
The ovarian cancer segment is expected to have the highest CAGR during the forecast period. This targeted approach minimizes damage to surrounding healthy tissue. However, regulatory approvals, safety considerations, and the need for further clinical evidence may impact their widespread adoption. The evolving landscape of ovarian cancer treatments and research will influence the role of alpha emitters in addressing this challenging disease.
Region with largest share:
North America is projected to hold the largest market share during the forecast period due to increasing applications in medical treatments, particularly in cancer therapy. Growing investments in nuclear power and research and development activities contribute to market expansion. Public perception and regulatory compliance remain pivotal factors influencing the growth of alpha emitters in the region.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period due to increasing applications in medical treatments, research, and nuclear power generation. Rising prevalence of cancer fuels demand for targeted alpha-particle radiotherapy. The region’s expanding healthcare sector and research activities contribute to the region's potential, but ongoing developments and adherence to safety protocols will play pivotal roles in shaping the trajectory of the market in this region.
Key players in the market
Some of the key players in Alpha Emitter market include Orano Group, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Novartis International AG, Bayer AG, NorthStar Medical Radioisotopes, Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Ltd, Eckert & Ziegler, RadioMedix, Curium Pharma, Isotopen Technologien München AG (ITM), Nordion Inc..
Key Developments:
In November 2022, IONETIX Corporation, a molecular imaging diagnostics and therapeutics company, announced that the U.S. Nuclear Regulatory Commission (NRC) had issued a Materials License for its new production facility located in Michigan, U.S.
In June 2022, Alpha Tau Medical Ltd., a medical technology company announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational Device Exemption (IDE) application to start its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using Alpha DaRT.
Types Covered:
• Lead
• Astatine
• Bismuth
• Radium
• Actinium
• Other Types
Sources Covered:
• Artificially Produced Sources
• Natural Sources
Applications Covered:
• Prostate Cancer
• Neuroendocrine Tumors
• Bone Metastases
• Ovarian Cancer
• Other Applications
End Users Covered:
• Specialty Clinics
• Diagnostic Centers
• Hospitals
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Researh Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Alpha Emitter Market, By Type
5.1 Introduction
5.2 Lead
5.3 Astatine
5.4 Bismuth
5.5 Radium
5.6 Actinium
5.7 Other Types
6 Global Alpha Emitter Market, By Source
6.1 Introduction
6.2 Artificially Produced Sources
6.3 Natural Sources
7 Global Alpha Emitter Market, By Application
7.1 Introduction
7.2 Prostate Cancer
7.3 Neuroendocrine Tumors
7.4 Bone Metastases
7.5 Ovarian Cancer
7.6 Other Applications
8 Global Alpha Emitter Market, By End User
8.1 Introduction
8.2 Specialty Clinics
8.3 Diagnostic Centers
8.4 Hospitals
8.5 Other End Users
9 Global Alpha Emitter Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Orano Group
11.2 Alpha Tau Medical Ltd
11.3 Actinium Pharmaceutical Inc.
11.4 Novartis International AG
11.5 Bayer AG
11.6 NorthStar Medical Radioisotopes
11.7 Fusion Pharmaceuticals Inc.
11.8 Telix Pharmaceuticals Ltd
11.9 Eckert & Ziegler
11.10 RadioMedix
11.11 Curium Pharma
11.12 Isotopen Technologien München AG (ITM)
11.13 Nordion Inc.
List of Tables
1 Global Alpha Emitter Market Outlook, By Region (2021-2030) ($MN)
2 Global Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
3 Global Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
4 Global Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
5 Global Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
6 Global Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
7 Global Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
8 Global Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
9 Global Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
10 Global Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
11 Global Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
12 Global Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
13 Global Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
14 Global Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
15 Global Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
16 Global Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
17 Global Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
18 Global Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
19 Global Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
20 Global Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
21 Global Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
22 Global Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
23 North America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
24 North America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
25 North America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
26 North America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
27 North America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
28 North America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
29 North America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
30 North America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
31 North America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
32 North America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
33 North America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
34 North America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
35 North America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
36 North America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
37 North America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
38 North America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
39 North America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
40 North America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
41 North America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
42 North America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
43 North America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
44 North America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
45 Europe Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
46 Europe Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
47 Europe Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
48 Europe Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
49 Europe Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
50 Europe Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
51 Europe Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
52 Europe Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
53 Europe Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
54 Europe Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
55 Europe Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
56 Europe Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
57 Europe Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
58 Europe Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
59 Europe Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
60 Europe Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
61 Europe Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
62 Europe Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
63 Europe Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
64 Europe Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
65 Europe Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
66 Europe Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
67 Asia Pacific Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
68 Asia Pacific Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
69 Asia Pacific Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
70 Asia Pacific Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
71 Asia Pacific Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
72 Asia Pacific Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
73 Asia Pacific Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
74 Asia Pacific Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
75 Asia Pacific Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
76 Asia Pacific Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
77 Asia Pacific Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
78 Asia Pacific Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
79 Asia Pacific Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
80 Asia Pacific Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
81 Asia Pacific Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
82 Asia Pacific Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
83 Asia Pacific Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
84 Asia Pacific Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
85 Asia Pacific Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
86 Asia Pacific Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
87 Asia Pacific Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
88 Asia Pacific Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
89 South America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
90 South America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
91 South America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
92 South America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
93 South America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
94 South America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
95 South America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
96 South America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
97 South America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
98 South America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
99 South America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
100 South America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
101 South America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
102 South America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
103 South America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
104 South America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
105 South America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
106 South America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
107 South America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
108 South America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
109 South America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
110 South America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
111 Middle East & Africa Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
112 Middle East & Africa Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
113 Middle East & Africa Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
114 Middle East & Africa Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
115 Middle East & Africa Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
116 Middle East & Africa Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
117 Middle East & Africa Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
118 Middle East & Africa Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
119 Middle East & Africa Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
120 Middle East & Africa Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
121 Middle East & Africa Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
122 Middle East & Africa Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
123 Middle East & Africa Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
124 Middle East & Africa Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
125 Middle East & Africa Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
126 Middle East & Africa Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
127 Middle East & Africa Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
128 Middle East & Africa Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
129 Middle East & Africa Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
130 Middle East & Africa Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
131 Middle East & Africa Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
132 Middle East & Africa Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
